Carmen Varela

发表

Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.

J. Bischoff, R. Álvarez, M. I. Albarrán, 2017, Bioorganic & medicinal chemistry letters.

Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors.

J. Oyarzábal, C. Blanco-Aparicio, R. Álvarez, 2020, European journal of medicinal chemistry.

Synthesis of Tetracyclic Analogues of Calcitriol (1α,25‐Dihydroxyvitamin D3) with Side‐Chain‐Locked Spatial Orientations at C(20)

K. Nilsson, A. Mouriño, M. Torneiro, 2002 .

Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.

M. Barbacid, F. Mulero, P. Pizcueta, 2012, Bioorganic & medicinal chemistry letters.

Identification of ETP-46321, a Potent and Orally Bioavailable PI3K α, δ Inhibitor.

M. Barbacid, F. Mulero, P. Pizcueta, 2012 .

Differentiation between [1,2,4]triazolo[1,5‐a] pyrimidine and [1,2,4]triazolo[4,3‐a]‐ pyrimidine regioisomers by 1H15N HMBC experiments

P. Pevarello, A. Salgado, Carmen Varela, 2010, Magnetic resonance in chemistry : MRC.

New use of bis(benzotriazolyl)-1,2-(dialkylamino)ethanes for the synthesis of 2-H-3-dialkylamino imidazo[1,2-a]pyrazine derivatives

A. Salgado, J. Pastor, Sonia Martínez, 2012 .

Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.

O. Rabal, J. Oyarzábal, J. Bischoff, 2019, European journal of medicinal chemistry.

Synthesis of [1,2,4]-triazolo[1,5-a]pyrimidines by Dimroth rearrangement of [1,2,4]-triazolo[4,3-a]pyrimidines: A theoretical and NMR study

J. Elguero, P. Pevarello, A. Salgado, 2011 .

Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.

O. Rabal, J. Oyarzábal, J. Bischoff, 2012, Bioorganic & medicinal chemistry letters.

Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

M. Barbacid, C. Guerra, D. Santamaría, 2020, Proceedings of the National Academy of Sciences.

Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors.

N. Ajenjo, C. Blanco-Aparicio, R. Álvarez, 2021, ACS medicinal chemistry letters.

Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.

M. Barbacid, F. Mulero, P. Pizcueta, 2012, Bioorganic & medicinal chemistry letters.